Fresenius Kabi
global healthcare committed life
- B2B
- B2G
- Has physical offices
- Manufacturing
- Sales-led purchase
About Fresenius Kabi
Global provider therapies, medical products. Focuses on medicines, technologies for critically, chronically ill patients. Biosimilars, nutrition, medical devices, generics.
Key facts
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,000+ employees
- Headquarters
- Bad Homburg, Hessen, Germany
- Revenue
- €8.6BFY2025, publicly reported
- Website
- fresenius-kabi.com
Jobs at Fresenius Kabi
- ALTERNANT(E) - CHARGE(E) RESSOURCES HUMAINES (H/F)
- Assistant(e) Chef de produit Perfusion & Générique
- Global Manufacturing Project Controller (m/f/d)
- Quality Assurance Specialist/Quality Operations (m/w/d)
- Global S&OP Lead Biopharma (m/f/d)
- Technical Expert - Production
- Global Digital Systems & Martech Manager (m/f/d) - MLR & DAM
- Senior Program Manager, Global Quality IT Platforms (m/f/d)
Fresenius Kabi in the news
- Five biosimilar manufacturers attack Millenium’s Entyvio patents in London
Multiple biosimilar manufacturers, including Fresenius Kabi, are engaged in patent disputes against Millennium's Entyvio in the UK, France, and the Netherlands to clear the path for their generic versions.
- Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals
Fresenius Kabi and AABB announced the 21st annual Blood Collectors Week to honor blood collection professionals for their life-saving work.
- Die Fresenius-Aktie legt nach dem Sugammadex-Start zu
Fresenius Kabi launched a generic Sugammadex injection in the US, impacting Fresenius' stock performance and outlook.
- FDA warns Fresenius over leaking sterile drug bags and GMP failures
Fresenius Medical Care received an FDA warning for cGMP violations at its Utah facility due to leaking sterile peritoneal dialysis solution bags and insufficient quality control, following a separate recall by Fresenius Kabi.
- Die Fresenius-Aktie profitiert von Q2-2026-Wachstum und Produktneuheit
Fresenius stock is stable in the mid-40 EUR range, driven by strong Q2 2026 growth and the launch of a new generic drug by Fresenius Kabi in the US.
Fresenius Kabi at a glance
Fresenius Kabi is a B2B/B2G company in the Pharmaceutical Manufacturing industry, headquartered in Bad Homburg, Hessen, Germany.
Fresenius Kabi has 10,000+ employees.
Fresenius Kabi's revenue is €8.6B (FY2025, publicly reported).
Fresenius Kabi is hiring: 8 recent open roles, including ALTERNANT(E) - CHARGE(E) RESSOURCES HUMAINES (H/F), Assistant(e) Chef de produit Perfusion & Générique, Global Manufacturing Project Controller (m/f/d).
Selling to companies like Fresenius Kabi?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies